Literature DB >> 27574579

Current Trends in Identifying Rapidly Acting Treatments for Depression.

Dawn F Ionescu1, George I Papakostas2.   

Abstract

Traditional antidepressant medications generally take weeks-to-months to achieve effect. However, the breakthrough finding of ketamine's rapidly acting antidepressant properties has inspired a decade-and-a-half of progress towards the identification of treatments that work quickly-within hours-to-days. This paradigm-shift in the discovery of antidepressant therapies has significantly changed the current landscape of antidepressant drug development. Building on this, the current review briefly highlights the recent trends in research towards identifying rapidly-acting antidepressants. Specifically, ketamine, GLYX-13, nitrous oxide, metabotropic glutamatergic receptor modulators, scopolamine, opioid-receptor modulators, and low field magnetic stimulation are discussed.

Entities:  

Keywords:  Depression; GLYX-13; LFMS; experimental therapeutics; kappa-opioid receptor; ketamine; major depressive disorder; metabotropic glutamatergic receptor (mGluRs) modulators; nitrous oxide; psychopharmacology; rapid treatments; scopolamine; treatment-resistant depression

Year:  2016        PMID: 27574579      PMCID: PMC5001565          DOI: 10.1007/s40473-016-0075-4

Source DB:  PubMed          Journal:  Curr Behav Neurosci Rep


  51 in total

Review 1.  A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.

Authors:  David A Mrazek; John C Hornberger; C Anthony Altar; Irina Degtiar
Journal:  Psychiatr Serv       Date:  2014-08-01       Impact factor: 3.084

Review 2.  NMDA antagonist treatment of depression.

Authors:  Nolan R Williams; Alan F Schatzberg
Journal:  Curr Opin Neurobiol       Date:  2015-12-11       Impact factor: 6.627

3.  Serial infusions of low-dose ketamine for major depression.

Authors:  Keith G Rasmussen; Timothy W Lineberry; Christine W Galardy; Simon Kung; Maria I Lapid; Brian A Palmer; Matthew J Ritter; Kathryn M Schak; Christopher L Sola; Allison J Hanson; Mark A Frye
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

4.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

5.  Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder.

Authors:  Dan V Iosifescu; Nicolas R Bolo; Andrew A Nierenberg; J Eric Jensen; Maurizio Fava; Perry F Renshaw
Journal:  Biol Psychiatry       Date:  2008-01-22       Impact factor: 13.382

6.  Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.

Authors:  Boadie W Dunlop; Paula G Davis
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

8.  Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Arun V Ravindran; Sidney H Kennedy; M Claire O'Donovan; Angelo Fallu; Fernando Camacho; Carin E Binder
Journal:  J Clin Psychiatry       Date:  2008-01       Impact factor: 4.384

9.  Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.

Authors:  Rebecca B Price; Dan V Iosifescu; James W Murrough; Lee C Chang; Rayan K Al Jurdi; Syed Z Iqbal; Laili Soleimani; Dennis S Charney; Alexandra L Foulkes; Sanjay J Mathew
Journal:  Depress Anxiety       Date:  2014-03-25       Impact factor: 6.505

10.  Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-resistant Major Depression.

Authors:  Chun Yang; Kenji Hashimoto
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

View more
  4 in total

1.  Gender-Related Hippocampal Proteomics Study from Young Rats After Chronic Unpredicted Mild Stress Exposure.

Authors:  Lin-Na Ning; Teng Zhang; Jiang Chu; Na Qu; Li Lin; Ying-Yan Fang; Yan Shi; Peng Zeng; Er-Li Cai; Xiao-Ming Wang; Qun Wang; You-Ming Lu; Xin-Wen Zhou; Qi Zhang; Qing Tian
Journal:  Mol Neurobiol       Date:  2017-01-07       Impact factor: 5.590

2.  Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Authors:  Naji C Salloum; Maurizio Fava; Rebecca S Hock; Marlene P Freeman; Martina Flynn; Bettina Hoeppner; Cristina Cusin; Dan V Iosifescu; Madhukar H Trivedi; Gerard Sanacora; Sanjay J Mathew; Charles Debattista; Dawn F Ionescu; George I Papakostas
Journal:  J Affect Disord       Date:  2019-09-03       Impact factor: 4.839

3.  A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Authors:  G I Papakostas; K Johe; H Hand; A Drouillard; P Russo; G Kay; R Kashambwa; B Hoeppner; M Flynn; A Yeung; M A Martinson; M Fava
Journal:  Mol Psychiatry       Date:  2019-01-09       Impact factor: 15.992

Review 4.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.